Table 1.
Characteristics of included studies evaluating Chikungunya antibody or antigen-based rapid diagnostic tests, 2005–2018.
Fig 1.
Number of CHIKV RDTs developed or commercialized for POC application by country of manufacture.
The world map was created, edited, and colored using Microsoft Excel for Mac, version 16.61.1. Public domain link to map base layer used in creating the figure is available: https://commons.wikimedia.org/wiki/File:BlankMap-World.svg. CHIKV, Chikungunya; POC, point-of-care; RDT, rapid diagnostic test.
Table 2.
Characteristics of Chikungunya rapid diagnostic tests developed or commercialized for point-of-care application.
Table 3.
Summary of diagnostic assessments of Chikungunya antibody or antigen-based rapid diagnostic tests, 2005–2018.
Fig 2.
Summary of diagnostic accuracy studies evaluating the OnSite Chikungunya IgM Combo Rapid test (CTK Biotech, Poway, CA, USA) and the SD BIOLINE Chikungunya IgM test (Standard Diagnostics, Yongin-si, South Korea).
Fig 3.
QUADAS-2 assessment of studies.
Fig 4.
CHIKV RDTs: Fragmented landscape presents market challenges and opportunities for interventions.
CHIKV, Chikungunya; RDT, rapid diagnostic test; WHO, World Health Organization.
Fig 5.
Future needs of immunoassay-based rapid diagnostic tests for CHIKV infection.
CHIKV, Chikungunya; RDT, rapid diagnostic test; WHO, World Health Organization.